Drug Information

Drug General Information
Drug ID
D03ELL
Former ID
DAP000848
Drug Name
Amisulpride
Synonyms
Aminosultopride; Amisulpiride; Amisulprida; Amisulpridum; Deniban; Socian; Solian; Amisulpride [INN]; DAN 2163; Amisulprida [INN-Spanish]; Amisulpride (INN); Amisulpridum [INN-Latin]; DAN-2163; Deniban (TN); Solian (TN); Solian, Amisulpride; SL-91.1077; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
Drug Type
Small molecular drug
Indication Schizophrenia [ICD9: 295; ICD10:F20] Approved [536361], [543330]
Therapeutic Class
Antipsychotic Agents
Company
Sanofi-Aventis
Structure
Download
2D MOL

3D MOL
Formula
C17H27N3O4S
InChI
InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)
InChIKey
NTJOBXMMWNYJFB-UHFFFAOYSA-N
CAS Number
CAS 53583-79-2
PubChem Compound ID
2159
PubChem Substance ID
4426036, 7978690, 8151467, 12013930, 14852985, 24890689, 26719747, 26719748, 26753203, 29221338, 46386656, 46386793, 49681614, 49875487, 50105670, 50740420, 51091647, 56311657, 57321177, 81041117, 81092862, 85208948, 85789065, 90341703, 91746200, 92308440, 92721951, 99437236, 99443244, 103527296, 104299778, 117878946, 121361831, 124658864, 124757136, 124801322, 124891581, 125001904, 125163940, 125312444, 125356672, 126592345, 126618690, 126660738, 126665652, 128751968, 131324616, 131342364, 131480773, 131849879
SuperDrug ATC ID
N05AL05
SuperDrug CAS ID
cas=071675859
Target and Pathway
Target(s) D(2) dopamine receptor Target Info Antagonist [535384], [536014], [536228]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Dopamine receptors
G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
References
Ref 536361Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
Ref 543330(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 963).
Ref 535384Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38.
Ref 536014Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs. 2004;18(13):933-56.
Ref 536228Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.